Vaccine efficacy tends to erode with age — a problem so entrenched it has shaped public health recommendations for decades. What makes the AS01-adjuvanted recombinant herpes zoster vaccine (RZV) different is that it appears to sidestep this decline, and a new randomized controlled trial has begun to reveal the immunological machinery behind that advantage.
In a partially placebo-controlled study enrolling 84 young adults (18–35) and 63 older adults (≥60), participants received either RZV or an inactivated quadrivalent seasonal influenza vaccine (IIV4). RZV produced markedly superior cellular immunity in both age cohorts: robust polyfunctional CD4+ T cell responses and elevated interferon-gamma (IFN-γ) from peripheral blood mononuclear cells. IIV4, by contrast, raised antibody titers but triggered minimal antigen-specific CD4+ T cell activity and no measurable IFN-γ elevation. Crucially, RZV appeared to reduce systemic inflammation in older participants — particularly after the second dose — and baseline inflammatory burden correlated inversely with both antibody production and IFN-γ output following vaccination.
This is a meaningful finding because chronic low-grade inflammation, often called inflammaging, is widely considered a central driver of immunosenescence. Most vaccines simply work around it; RZV may actively modulate it. The AS01B adjuvant system — combining MPL and QS-21 — is already known to amplify innate immune priming, but the suggestion that it might transiently dampen systemic inflammation rather than exacerbate it is counterintuitive and warrants replication. Limitations include the relatively modest cohort size, short-term immunological endpoints, and the absence of longitudinal efficacy data within this trial. Still, RZV's 82% durable protection at 11 years in adults over 50 lends real-world weight to these mechanistic clues. This study is incremental but directionally important: it frames the AS01B platform as a potential template for re-engineering age-resistant vaccines across other pathogens.